SEPTInvestingStart Free
Stocks/ARTV/SEC Filings/8-K Nov 9, 2026

ARTV 8-K: SEC filing

Artiva Biotherapeutics

Filed with the SEC on Nov 9, 2026 · accession 0001193125-26-453580

ARTV filed a 8-K (current report) with the SEC on Nov 9, 2026. Artiva Biotherapeutics filed an 8-K/A disclosing estimated costs for its previously announced wind-down, including discontinuation of its AlloNK (AB-101) clinical program and a workforce reduction of approximately 94%. The stock moved +1.7% by the first close after the filing.

Summary of the filing

Artiva Biotherapeutics filed an 8-K/A disclosing estimated costs for its previously announced wind-down, including discontinuation of its AlloNK (AB-101) clinical program and a workforce reduction of approximately 94%. The company estimates $10-15 million in contract termination/clinical trial close-out costs and $17-20 million in workforce reduction costs.

For details, click here →How to read a 8-K →

Key details

Estimated contract termination and other costs related to discontinuation and close-out of AlloNK clinical trials$12.5M
Estimated costs related to workforce reduction including severance, benefits, payroll taxes and other termination costs$18.5M
RegistrantArtiva Biotherapeutics, Inc.
Chief executive officerFred Aslan

How ARTV stock reacted

Close before

$4.15

Nov 6, 2026

First close after

+1.69%

$4.22

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ARTV, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ARTV?

Click here

Frequently asked questions

What did ARTV file with the SEC on Nov 9, 2026?

ARTV filed a 8-K (SEC filing). Artiva Biotherapeutics filed an 8-K/A disclosing estimated costs for its previously announced wind-down, including discontinuation of its AlloNK (AB-101) clinical program and a workforce reduction of approximately 94%. The company estimates $10-15 million in contract termination/clinical trial close-out costs and $17-20 million in workforce reduction costs.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did ARTV stock react to this filing?

ARTV closed at $4.15 before the filing and $4.22 on Nov 9, 2026 (+1.69%).

Other ARTV SEC filings

  • 10-Q · SEC filingNov 9, 2026
  • 8-K · SEC filingOct 27, 2026
  • 8-K · SEC filingSep 11, 2026
  • SCHEDULE 13G/A · SEC filingAug 14, 2026
  • SCHEDULE 13G/A · SEC filingAug 10, 2026
  • S-3 · Shelf registrationAug 6, 2026
  • 10-Q · SEC filingAug 6, 2026
  • 8-K · SEC filingAug 6, 2026
  • DEF 14A · Board changeAug 3, 2026
  • 8-K · SEC filingJul 22, 2026

Get alerts when ARTV files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ARTV overviewARTV analysisARTV newsLatest SEC filings
Source: SEC EDGAR filing 0001193125-26-453580. The summary and key details are extracted by SEPT from the filing and may contain errors. Price reaction uses daily closing prices. Not financial advice.